These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 6432198)

  • 1. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
    Roald OK; Seem E
    Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
    Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
    Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000954. PubMed ID: 10796396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker.
    Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G
    Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173
    [No Abstract]   [Full Text] [Related]  

  • 11. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
    Dormandy JA; Berent A; Downes SJ
    Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.
    Marasini B; Bassani C
    Br J Clin Pharmacol; 1990 Dec; 30(6):847-51. PubMed ID: 2288831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
    Longstaff J; Gush R; Williams EH; Jayson MI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International study of ketanserin in Raynaud's phenomenon.
    Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
    Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketanserin and capillary flow in Raynaud's phenomenon.
    Tooke JE; Williams SA; Rawlinson DW; Black C
    Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.